Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827

✍ Scribed by Wojciech Bartminski

• Book ID: 117805532
• Publisher: Elsevier
• Year: 2009
• Weight: 146 KB
• Volume: 15
• Category: Article
• ISSN: 2173-5115
• DOI: 10.1016/s2173-5115(09)70132-0